On Dec. 20th 2007, Livzon Pharmaceutical Group Inc. announced that llaprazole had been approved by SFDA and it had got the drug approval certificate.
Llaprazole is a proton pump inhibitor (PPI) in the same pharmacologic class as omeprazole, used for peptic ulcer, duodenal ulcer, gastroesophageal reflux disease and other Acid-Related disorders.
In 2001, Livzon Pharmaceutical Group got the exclusive right from IL YANG Pharmaceutical Co. (South Korea) to develop and sale llaprazole in China. Livzon will be the first company to launch llaprazole in the whole world. It is expected that llaprazole can be put into market in the first half of 2008 at the soonest.